Compliance issues in the treatment of HIV infection

American Journal of Health-System Pharmacy

Volumn 55, Issue 17, 1998, Pages 1817-1824

  Tseng, Alice Lin In ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ASTEMIZOLE; BENZODIAZEPINE; CISAPRIDE; DELAVIRDINE; EFAVIRENZ; FEXOFENADINE; INDINAVIR; LORATADINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TERFENADINE; UNCLASSIFIED DRUG;

ADULT; DRUG INDUCED DISEASE; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PARESTHESIA; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; THRUSH; VIRUS INFECTION;

EID: 0032168998     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.17.1817     Document Type: Review

References (35)

1. McDonald CK, Gerber JG. Drug prescription practices in a university hospital HIV clinic. Paper presented at Fourth National Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 23.
2. Deeks SG, Smith M, Holodniy M et al. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997; 277:145-53.
3. Swindells S, Gendelman HE. The new non-nucleoside reverse transcriptase inhibitors. Infect Med. 1996; 13:715-9,731.
4. Hammer SM, Katzenstein DA, Hughes MD et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996; 335:1081-90.
5. Blaschke TF. Noncompliance and resistance to protease inhibitors. Paper presented at Fourth National Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 25.
6. Besch CL, Morse E, Simon P et al., for the Terry Beirn Community Programs for Clinical Research on AIDS. Preliminary results of a compliance study within CPCRA 007 Combination Nucleoside Study (NuCombo). Paper presented at Fourth National Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 23.
7. Chesney MA. New antiretroviral therapies: adherence challenges and strategies. Paper presented at Symposium on Evolving HIV Treatments: Advances and the Challenge of Adherence. Toronto, Canada; 1997 Sep 27.
8. Balestra P, Ferri F, Galgani S et al. Clinical, psychological and behavioural characteristics of HIV patients reporting low compliance to treatments. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 9.
9. Samet JH, Libman H, Steger KA et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992; 92:495-502.
10. Muma RD, Ross MW, Parcel GS et al. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995-7:439-47.
11. Schapiro JM, Winters MA, Stewart F et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996; 124:1039-50.
12. Vanhove GR, Schapiro JM, Winters MA et al. Patient compliance and drug failure in protease inhibitor monotherapy JAMA. 1996; 276:1955-6.
13. Raboud JM, Montaner JSG, Rae S et al. Predictors of duration of plasma viral load suppression. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 Sep 30.
14. Patick AK, Mo H, Markowitz M et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother. 1996; 40:292-7.
15. Patick AK, Duran M, Cao Y et al. Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. Paper presented at Fifth Workshop on HIV Drug Resistance. Whistler, Canada; 1996 Jul 3.
16. Sampson MS, Barr MR, Torres RA et al. Viral load changes in nelfinavir treated patients switched to a second protease inhibitor after loss of viral suppression. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 Oct 1.
17. Deeks S, Grant R, Horton C et al. Virologic effect of ritonavir plus saquinavir in subjects who have failed indinavir. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 Oct 1.
18. Sampson M, Torres RA, Stein AJ et al. Ritonavir-saquinavir combination treatment in protease inhibitor experienced patients with advanced HIV disease. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 Sep 29.
19. Sackett DL, Haynes RB. Compliance with therapeutic regimens. Baltimore: Johns Hopkins Univ. Press; 1976.
20. Henderson T, Hall J, Lipton T. Changing self-destructive behaviors. In: Stone G, ed. Health psychology: a handbook. San Francisco: Jossey-Bass; 1979.
21. Leventhal H, Safer MA, Panagis DM. The impact of communications on the self-regulation of health beliefs, decisions and behavior. Health Educ Q. 1983; 10:3-29.
22. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med. 1984; 100:258-68.
23. Leventhal H, Cameron L. Behavioral theories and the problem of compliance. Patient Educ Couns. 1987; 10:117-38.
24. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm. 1991; 48:1978-88.
25. Singh N, Squier C, Sivek C et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996; 8:261-9.
26. Aversa SL, Kimberlin C. Psychosocial aspects of antiretroviral medication use among HIV patients. Patient Educ Couns. 1996; 29:207-19.
27. Aboulker JP, Swart AM. Preliminary analysis of the Concorde trial. Lancet. 1993; 341:889-90.
28. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 1994; 343:871-81.
29. Reynes J. Stadi study: once daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. Paper presented at European Zerit Symposium. Cannes, France; 1997 Mar 22.
30. Petrak RM, Boyer N, Hines D et al. A study to evaluate the clinical and virologic efficacy of a Crixivan, ddI, and d4T combination. Paper presented at 35th Annual Meeting of the Infectious Diseases Society of America. San Francisco CA; 1997 Sep 13-16.
31. Keiser P, Turner D, Ramilo O et al. An open label, pilot study of the efficacy and tolerability of once daily ddI versus twice daily ddI. Paper presented at 35th Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA; 1997 Sep 13-16.
32. Crixivan product monograph. West Point, PA: Merck Frosst USA; 1996.
33. Viracept product monograph. La Jolla, CA: Agouron Pharmaceuticals; 1997.
34. From compliance to concordance: towards shared goals in medicine taking. London: Royal Pharmaceutical Society of Great Britain; 1997.
35. Clepper I. Noncompliance. The invisible epidemic. Drug Top. 1992; 136(16):44,45,49,50,56,59,60,62,65.